DOCSLIB.ORG

Auditor Disclosure Data.Xlsx

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Auditor Disclosure Data.Xlsx 2021 ASCO Annual Meeting Auditors All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Name Employment Leadership Stock and Other Honoraria Consulting or Advisory Speakers' Bureau Research Funding Patents, Royalties, Expert Testimony Travel, Other Relationship (OPTIONAL) (OPTIONAL) Open Ownership Interests Role Other Intellectual Accommodations, Uncompensated Payments Link Property Expenses Relationships Patrick Burke Lilly (I), Eisai (I) Novartis (Inst), Takeda (Inst) Sham Mailankody Physician Education Juno Therapeutics (Inst), Resource, Plexus Takeda (Inst), Janssen Oncology (Inst), Allogene (Inst), Bristol-Myers Squibb (Inst) Lisa Law Mary Cianfrocca Roche/Genentech Roche/Genentech Brian O'Sullivan IBA, Merck, Pfizer Erica Stringer-Reasor Breast Cancer Index, Lilly, Immunomedics, Novartis, Lilly Susan G. Komen for the Cascadian Therapeutics, Genentech https://openpayments Mylan Lilly, OncoSec Cure, V Foundation Lilly data.cms.gov/physician /974630 Rodabe Amaria Iovance Biotherapeutics, Merck (Inst), Bristol-Myers Nektar, Novartis Squibb (Inst), Novartis (Inst), Array BioPharma (Inst), Genentech (Inst), Iovance Biotherapeutics (Inst) Julia White Intraop Medical (Inst) Fabrice Andre Pegacsy AstraZeneca (Inst), Novartis, Roche, Novartis (Inst), Pfizer GlaxoSmithKline, (Inst), Lilly (Inst), Roche AstraZeneca (Inst), Daiichi (Inst) Kunal Kadakia Kathleen Moore Research To Practice, Genentech/Roche, PTC Therapeutics (Inst), Prime Oncology, Physician Immunogen, AstraZeneca Lilly (Inst), Merck (Inst), Education Resource (Inst), Tesaro (Inst), VBL Tesaro (Inst), Genentech Therapeutics, Merck, (Inst), Clovis Oncology Aravive, Pfizer/EMD (Inst), Lilly Foundation Serono, Eisai, Abbvie, (Inst), Regeneron (Inst), Vavotar, Mersana (Inst), Advaxis (Inst), Bristol- Myriad Genetics Myers Squibb (Inst), Verastem (Inst), Novartis Pharmaceuticals UK (Inst), AstraZeneca (Inst), Agenus (Inst), Takeda (Inst), Forty Seven (Inst), Immunogen (Inst), Bayer (Inst), Novogen (Inst), Abbvie/Stemcentrx (Inst) Leslie Ballas University of Southern California Keck School of Medicine Benedito Carneiro Tempus, EMD Serono, Abbvie (Inst), Pfizer (Inst), Foundation Medicine Bayer (Inst), AstraZeneca/ MedImmune (Inst), Astellas Pharma (Inst), Actuate Therapeutics (Inst) Walid Shaib Ipsen, Lexicon, Bristol- ArQule (Inst), Lilly (Inst), Lexicon Myers Squibb, Blueprint Basilea (Inst), Lexicon Medicines, Natter, Mylan (Inst) Ishmael Jaiyesimi Edgardo Santos Genentech/Roche, Pfizer, Amgen, Boehringer Ingelheim, Merck, Novartis, AstraZeneca, Takeda, Sanofi Genzyme, Lilly, Astellas Pharma, G1 Therapeutics Ryan Gentzler Jimmy Ruiz AstraZeneca AstraZeneca, Genentech AstraZeneca (Inst), Roche AstraZeneca, (Inst), BeyondSpring Genentech/Roche Pharmaceuticals (Inst), ER Squibb Andrew McKenzie Andrew Seidman Genomic Health, Eisai, Genentech/Roche, Eisai, Genomic Health, Eisai, Bayer, Odonate Lilly, Genentech/Roche, Novartis, Lilly, Odonate Genentech/Roche, Lilly, Therapeutics (Inst), Nektar Novartis, AstraZeneca, Therapeutics, Novartis/Pfizer, (Inst) Immunomedics BeyondSpring Genentech/Roche, Pharmaceuticals, Pfizer, AstraZeneca/ MedImmune Immunomedics Don Dizon InfiniteMD, NeuHope i-Mab, Clovis Oncology, Merck Sharp & Dohme https://openpayments AstraZeneca, Regeneron, (Inst), Bristol-Myers data.cms.gov/physician Tesaro Squibb (Inst), Kazia Pharmaceuticals (Inst), /744193/summary Tesaro (Inst) Emily Slotkin Eli Lilly and Company (Inst) Ignacio Garrido-Laguna Array BioPharma, Eisai Novartis (Inst), Ignyta (Inst), Halozyme (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Pfizer (Inst), MedImmune (Inst), Lilly (Inst), Incyte (Inst), GlaxoSmithKline (Inst), ARMO BioSciences (Inst), Tolero Pharmaceuticals (Inst), BridgeBio Pharma (Inst), Jacobio (Inst) Saad Usmani Celgene, Amgen, Janssen Celgene, Takeda, Amgen, Celgene, Array Oncology, Seattle Janssen Oncology, Sanofi BioPharma, Janssen Genetics, Takeda, Oncology, Pharmacyclics, GlaxoSmithKline, Sanofi, Bristol-Myers Karyopharm Therapeutics, Squibb, Amgen, Seattle Abbvie, SkylineDX, Merck, Genetics, Merck, Skyline Oncopeptides Diagnostics, GlaxoSmithKline Shilpa Gupta Nektar AstraZeneca, Exelixis, Bristol-Myers Squibb, Merck, Pfizer, Bristol- Bristol-Myers Squibb, Janssen Oncology, Myers Squibb, Seattle Merck Sharp & Dohme, Exelixis Genetics Seattle Genetics Rachel Grisham Mateon Therapeutics, Context Therapeutics EMD Serono Prime Oncology, MCM Verastem Clovis Oncology, (Inst) Education, OncLive, Regeneron, Aptiude Health GlaxoSmithKline Dax Kurbegov HCA Healthcare Bristol-Myers Squibb Novartis, Seattle Genetics, Varian Medical Systems, Lilly Amanda Walker AstraZeneca, Reflexion AstraZeneca Medical, RadImmune Simon Lo Elekta (Inst) Gregory Cote PharmaMar, Epizyme, C4 Macrogenics (Inst), PharmaMar Therapeutics Boston Biomedical (Inst), PharmaMar (Inst), Epizyme (Inst), Agios (Inst), Eisai (Inst), Merck KGaA (Inst), Plexxikon (Inst), CBA (Inst), Bavarian Nordic, Bayer (Inst), Springworks Therapeutics (Inst) Ajay Nooka Amgen, Janssen Amgen (Inst), Janssen GlaxoSmithKline Oncology, Celgene, Bristol- Oncology (Inst), Takeda Myers Squibb, (Inst) GlaxoSmithKline, Takeda, Oncopeptides, Karyopharm Therapeutics, Adaptive Biotechnologies, Genzyme Mohamed Salem Taiho Pharmaceutical, Genentech/Roche, Taiho Exelixis, Bristol-Myers Pharmaceutical Squibb Marina Garassino MSD Oncology, Bristol-Myers Squibb, AstraZeneca, Takeda, Bristol-Myers Squibb Pfizer, Roche, AstraZeneca/ MSD, AstraZeneca, MSD Oncology, Celgene, (Inst), MSD (Inst), AstraZeneca MedImmune, Novartis, Takeda, Roche, Incyte, Roche, Bristol- Roche/Genentech (Inst), GlaxoSmithKline, Takeda, Tiziana Life Sciences, Myers Squibb, Otsuka, Eli AstraZeneca/ MedImmune Roche, Bristol-Myers Sanofi/Aventis, Celgene, Lilly (Inst), AstraZeneca (Inst), Squibb Daiichi Sankyo, Inivata, Pfizer (Inst), Incyte, Pfizer, Seattle GlaxoSmithKline (Inst), Genetics, Eli Lilly, Novartis (Inst), Merck GlaxoSmithKline, Bayer (Inst), Incyte (Inst), Takeda Healthcare (Inst), Spectrum Pharmaceuticals, Blueprint Pharmaceuticals (Inst), Medicines, Janssen, Blueprint Medicines (Inst), Regeneron Eli Lilly (Inst), Ipsen (Inst), Janssen (Inst), Exelixis (Inst), MedImmune (Inst), Sanofi (Inst), Pfizer (Inst), Amgen (Inst) Michael Sabel Watermark Research Breast Cancer Ally and Partners Melanoma Ally mobile technologies Edward Garon Dracen, EMD Serono, Merck (Inst), Genentech Novartis, GlaxoSmithKline, (Inst), AstraZeneca (Inst), Merck, Boehringer Novartis (Inst), Lilly (Inst), Ingelheim, Shionogi, Eisai, Bristol-Myers Squibb Bristol-Myers Squibb, ABL (Inst), Mirati Therapeutics Bio, Sanofi, Xilio (Inst), Dynavax (Inst), Iovance Biotherapeutics (Inst), Neon Therapeutics (Inst), EMD Serono (Inst) Mairead McNamara Novartis Ipsen, Shire, Sirtex NuCana BioMed NuCana BioMed, Ipsen, Bayer, Novartis Medical, Incyte Servier Bradley Carthon Eisai, Bristol-Myers Squibb Alkermes (Inst), Bristol-Myers Squibb Foundation, MedImmune (Inst), Merck Immunomedics (Inst) Suparna Wedam Joanne Jeter Pfizer, Array BioPharma Merck, Bristol-Myers Pfizer, Array BioPharma Squibb (Inst) Shadia Jalal Adaptimmune AstraZeneca/ MedImmune, Tesaro, Astex Pharmaceuticals Milos Miljkovic Maura Gillison Bristol-Myers Squibb, Bristol-Myers Squibb Merck, EMD Serono, (Inst), Genocea Roche, Kura, BioNTech, Biosciences (Inst), Shattuck, Bayer, Cullinan (Inst) Debiopharm Group, Ipsen, Gilead Sciences, Bicara Therapeutics, BioNTech AG Ezra Cohen Bayer, MSD, Merck, Regeneron, BioNTech, Eisai, Gilead Gina D'Amato Blueprint Medicines, Epiz, Deciphera, Daiichi Sankyo/Lilly Efrat Dotan Pfizer, Boston Medical ARMO BioSciences Pfizer (Inst), Bayer (Inst), Incyte (Inst), Boston Biomedical (Inst), Merck (Inst), MedImmune (Inst), GlaxoSmithKline (Inst), Lilly (Inst), AstraZeneca (Inst) Ramon Andrade de Mello AstraZeneca, Novartis, Pfizer, Zodiac, MSD AstraZeneca Amgen, Roche, Merck, Astellas Pharma, Merck Oncology Pierre Fabre, Serono, Eurofarma AstraZeneca, Bristol- Myers Squibb Brazil, Astellas Pharma William Kelly Janssen Oncology, Bayer Merck Sharp & Dohme Sanofi (Inst), Novartis Janssen Oncology, Merck (Inst), Janssen Oncology Sharp & Dohme (Inst), Bayer (Inst), Exelixis (Inst), Seattle Genetics (Inst), Endocyte (Inst), Amgen (Inst), BioClin Therapeutics (Inst), Sarah Cannon Research Institute (Inst), Hoffman-LaRoche (Inst) James Cleary Bristol-Myers Squibb Merck, Tesaro, Roche, Agios, Bristol- AstraZeneca, Esperas Myers Squibb Pharma, Abbvie (Inst), Merus (Inst), Roche/Genentech (Inst), Bristol-Myers Squibb (Inst) Cathy Eng Foundation Medicine, Natera, GlaxoSmithKline, Gilead/Forty Seven, Incyte, Mirati Therapeutics Jeremy Cetnar Gretchen Kimmick Boehringer Ingelheim, Eisai Roche (Inst), Genentech Royalties for Seattle Genetics, Novartis, Eisai, Genomic Health, (Inst), Abraxis BioScience CardioOncology textbook Foundation Medicine Agendia (Inst), Bristol-Myers from Springer, UpToDate Squibb (Inst), Puma Royalties Biotechnology (Inst), Wyeth (Inst), Novartis (Inst), GlaxoSmithKline (Inst), Johnson & Johnson (Inst), Pfizer (Inst) Ulka Vaishampayan Pfizer, Exelixis, Bayer, Pfizer, Bayer, Exelixis Astellas Pharma, Exelixis, Bristol-Myers Bristol-Myers Squibb, Squibb/Medarex, Merck Merck KGaA Serono, Advanced Accelerator Application, Alkermes, Helsinn Therapeutics Nina J. Karlin Thomas George Tempus Bristol-Myers Squibb https://openpayments (Inst), Merck (Inst), data.cms.gov/physician AstraZeneca/ MedImmune (Inst), Lilly (Inst), Bayer /321938/summary (Inst), Incyte (Inst),
Load more

Recommended publications
  • Moderna Appoints Oncology Leader Dr. Stephen Kelsey As President of Onkaido
    Moderna Appoints Oncology Leader Dr. Stephen Kelsey as President of Onkaido Former Genentech executive to lead Moderna’s first venture company, focused exclusively in novel biology for oncology drug development CAMBRIDGE, Mass., July 1, 2014— Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) TherapeuticsTM, a revolutionary treatment modality to enable the in vivo production of therapeutic proteins, announced today that Stephen Kelsey, M.D., will become president of Onkaido Therapeutics, Moderna’s oncology drug development company, effective July 21. Launched in January of this year, Onkaido is Moderna’s first venture company, focused exclusively on developing and commercializing mRNA-based oncology treatments. “As we continue to grow Moderna and perfect our mRNA Therapeutics platform, we are also focused on building a transformational oncology company that will benefit patients and society. This requires hiring the best oncology talent to lead Onkaido,” said Stéphane Bancel, president and founding chief executive officer, Moderna. “Steve brings a wealth of experience in oncology drug development to his new role. His knowledge and leadership, combined with the team of Onkaido scientists and Moderna’s innovative mRNA technology, will help speed a new class of cancer drugs to patients around the world.” Dr. Kelsey has extensive pharmaceutical industry experience in oncology. After 16 years as an academic clinician, he started his industry career at Sugen, and later was vice president of hematology/oncology at Genentech. While at Genentech, Dr. Kelsey played a significant role in the development of key products Perjeta®, Kadcyla® and Erivedge®, as well as other molecules in the company’s oncology portfolio. He left Genentech in 2009 to run Geron’s oncology division, where he served for four years as executive vice president, research and development, and chief medical officer helping to develop therapeutics and vaccines to fight cancer.
    [Show full text]
  • Print Layout 1
    TECHNICAL PROGRAM Monday, March 19 5:00 – 8:00 pm Welcome Reception Tuesday, March 20 8:00 – 10:00 Session 1: Setting the Conference Context and Drivers Chair: Geoff Slaff (Amgen) Roger Perlmutter (Amgen) Conquering the Innovation Deficit in Drug Discovery Helen Winkle (CDER, FDA) Regulatory Modernization 10:00 – 10:30 Break Vendor and poster review 10:30 – 12:30 Session 2: Rapid Cell Line Development and Improved Expression System Development Chairs: Timothy Charlebois (Wyeth) and John Joly (Genentech) Amy Shen (Genentech) Stable Antibody Production Cell-Line Development with an Improved Selection Process and Accelerated Timeline Mark Leonard (Wyeth) High-Performing Cell-Line Development within a Rapid and Integrated Platform Process Control Pranhitha Reddy (Amgen) Applying Quality-by-Design to Cell Line Development Lin Zhang (Pfizer) Development of a Fully-Integrated Automated System for High-Throughput Screening and Selection of Single Cells Expressing Monoclonal Antibodies 12:30 – 2:00 Lunch Vendor and poster review 2:00 – 4:30 Session 3: High-Throughput Bulk Process Development Chairs: Brian Kelley (Wyeth) and Jorg Thommes (Biogen Idec) Colette Ranucci (Merck) Development of a Multi-Well Plate System for High-Throughput Process Development Min Zhang (SAFC Biosciences) CHO Media Library – an Efficient Platform for Rapid Development and Optimization of Cell Culture Media Supporting High Production of Pharmaceutical Proteins in Chinese Hamster Ovary Cells Nigel Titchener-Hooker The Use of Ultra-Scale-Down Approaches to Enable Rapid Investigation
    [Show full text]
  • Genentech Tocilizumab Letter of Authority June 24 2021
    June 24, 2021 Hoffmann-La Roche, Ltd. C/O Genentech, Inc. Attention: Dhushy Thambipillai Regulatory Project Management 1 DNA Way, Bldg 45-1 South San Francisco, CA 94080 RE: Emergency Use Authorization 099 Dear Ms. Thambipillai: This letter is in response to Genentech, Inc.’s (Genentech) request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for the emergency use of Actemra1 (tocilizumab) for the treatment of coronavirus disease 2019 (COVID-19) in certain hospitalized patients, as described in the Scope of Authorization (Section II) of this letter, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes coronavirus disease 2019 (COVID-19).2 On the basis of such determination, the Secretary of HHS on March 27, 2020, declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to Section 564 of the Act (21 3 U.S.C. 360bbb-3), subject to terms of any authorization issued under that section. Actemra is a recombinant humanized monoclonal antibody that selectively binds to both soluble and membrane-bound human IL-6 receptors (sIL-6R and mIL-6R) and subsequently inhibits IL- 6-mediated signaling through these receptors.
    [Show full text]
  • PULSE: Speaker Biographies March 2019
    PULSE: Speaker Biographies March 2019 Supported by @BIA_UK www.bioindustry.org In order of appearance: Dr Barbara Domayne-Hayman Entrepreneur-in-residence, Francis Crick Institute, CBO, Autifony Therapeutics Ltd and formerly Chairman, Puridify Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in- residence. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee. Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School. Steve Bates, OBE CEO, BioIndustry Association Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
    [Show full text]
  • HY 2021 Results
    Roche HY 2021 results Basel, 22 July 2021 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • Companies in Attendance
    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
    [Show full text]
  • News Release
    NEWS RELEASE Media: Nikki Levy (650) 225-1729 Investor: Susan Morris (650) 225-6523 Biogen Idec Contacts: Media: Amy Brockelman (617) 914-6524 Investor: Eric Hoffman (617) 679-2812 GENENTECH AND BIOGEN IDEC ANNOUNCE POSITIVE RESULTS FROM A PHASE II TRIAL OF RITUXAN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass. – August 28, 2006 – Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that a Phase II study of Rituxan® (Rituximab) for relapsing-remitting multiple sclerosis (RRMS) met its primary endpoint. The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions observed on serial MRI scans of the brain at weeks 12, 16, 20 and 24 in the Rituxan-treated group compared to placebo. Genentech and Biogen Idec will continue to analyze the study results and will submit the data for presentation at an upcoming medical meeting. “These initial results exceeded our expectations,” said Hal Barron, M.D., Genentech senior vice president, development and chief medical officer. “Showing a significant benefit at 24 weeks in this small Phase II trial supports our hypothesis that selective B-cell targeted therapy may play an important role in the treatment of MS.” - more - - 2 - “Biogen Idec is committed to offering multiple options for people living with MS, a devastating disease. We are very encouraged by these data and look forward to learning more about the potential of Rituxan as a therapy to treat MS,” said Alfred Sandrock, M.D., Ph.D., senior vice president, neurology research and development, Biogen Idec.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • Halozyme, Inc. Protocol HALO-110-101 Amendment 3 CLINICAL STUDY PROTOCOL Title
    Halozyme, Inc. Protocol HALO-110-101 Amendment 3 NCT #: NCT03267940 CLINICAL STUDY PROTOCOL Title: A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Phase 1b Protocol Number: HALO-110-101 Original Protocol Date: 07 March 2017 Protocol Amendment 1 Date: 24 May 2017 Protocol Amendment 2 Date: 12 April 2018 Protocol Amendment 3 Date: 09 April 2019 IND: 102770 Sponsor: Halozyme, Inc. 11388 Sorrento Valley Road San Diego, CA 92121 Office: Confidential: This document and the information it contains are the property of Halozyme, Inc. and are provided for the sole and exclusive use of Investigators in this clinical study. The information in this document may not be disclosed unless such disclosure is required by Federal or applicable State Law or Regulations, or unless there is prior written consent from Halozyme, Inc. Subject to the foregoing, this information may be disclosed only to those persons involved in the clinical investigation who need it, and who share the obligation not to disseminate this information further. Halozyme, Inc. Protocol HALO-110-101 Amendment 3 Placeholder for Approval Signatures Halozyme, Inc. Protocol HALO-110-101 Amendment 3 1. SYNOPSIS Sponsor/Company
    [Show full text]
  • Genmab Announces Financial Results for the First Nine Months of 2020
    Genmab Announces Financial Results for the First Nine Months of 2020 November 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020 Highlights • Novartis granted U.S. FDA approval for Kesimpta® (ofatumumab) in relapsing multiple sclerosis • Janssen and European Myeloma Network achieved positive topline results from Phase 3 APOLLO study of daratumumab in relapsed or refractory multiple myeloma • Janssen was granted U.S. FDA approval for DARZALEX® (daratumumab) in combination with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma based on Phase 3 CANDOR study • DARZALEX net sales increased 35% compared to the first nine months of 2019 to USD 2,937 million, resulting in royalty income of DKK 2,898 million for the first nine months of 2020 • Genmab commenced binding arbitration of two matters under daratumumab license agreement with Janssen • Announcement of plan to transition Arzerra® (ofatumumab) to an oncology access program for chronic lymphocytic leukemia patients in the U.S. “Genmab continued to deliver on the promise of improving the lives of patients, with multiple regulatory milestones for Genmab-created products under development by our partners, including the exciting U.S. FDA’s approval of Kesimpta and the 8th U.S. FDA approval for DARZALEX,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “During the first nine months of 2020, with our solid financial footing Genmab has continued its focused investment in advancing its proprietary antibody product pipeline and building its capabilities as we evolve into a fully integrated biotech.” Financial Performance First Nine Months of 2020 • Revenue was DKK 8,067 million in the first nine months of 2020 compared to DKK 2,405 million in the first nine months of 2019.
    [Show full text]
  • Breaking Barriers with Pegvorhyaluronidase Alfa
    ADVERTISEMENT FEATURE Halozyme www.halozyme.com Breaking barriers with pegvorhyaluronidase alfa Halozyme is pioneering therapies that remodel the tumor microenvironment to increase accessibility for chemotherapies, immuno-oncology agents, and innate immune cells. Halozyme is developing pegvorhyaluronidase alfa (PEGPH20) to treat pancreatic and other solid tumors. Clinical-stage biotechnology company Halozyme Removal of HA by HA-High tumor microenvironment focuses on developing and commercializing cancer PEGPH20 in HA-high Cancer cell therapies that target the tumor microenvironment tumor animal models (TME). The cornerstone of Halozyme’s technology is was shown to: pegvorhyaluronidase alfa, a proprietary pegylated T cell • Decrease interstitial recombinant human hyaluronidase that degrades fluid pressure profile HA hyaluronan (HA), a glycosaminoglycan of repeating • Decompress PEGPH20 breaks up HA disaccharide subunits of N-acetylglucosamine and vasculature • Increase perfusion glucuronic acid, and a major contributor to the struc- Macrophage • Increase access for ture of the extracellular matrix and repair capacity of therapeutics tissues. High HA levels in the TME of solid tumors can • Increase immune cell access increase intratumoral pressure, resulting in decreased Decompressed tumor microenvironment perfusion, reduced drug delivery, and increased with increased immune cell access Vasculature chemoresistance. Pegvorhyaluronidase alfa is a first- Fig. 1 | Enlisting hyaluronidase to boost drug accessibility to tumors3. in-class biologic
    [Show full text]
  • Feasibility and First Reports of the MATCH-R Repeated Biopsy Trial At
    www.nature.com/npjprecisiononcology ARTICLE OPEN Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy Gonzalo Recondo 1, Linda Mahjoubi2, Aline Maillard3, Yohann Loriot1,4, Ludovic Bigot1, Francesco Facchinetti1, Rastislav Bahleda2, Anas Gazzah2, Antoine Hollebecque2, Laura Mezquita4, David Planchard1,4, Charles Naltet4, Pernelle Lavaud4, Ludovic Lacroix1,5,6, Catherine Richon5, Aurelie Abou Lovergne7, Thierry De Baere8, Lambros Tselikas8, Olivier Deas9, Claudio Nicotra2, Maud Ngo-Camus2, Rosa L. Frias1, Eric Solary10, Eric Angevin2, Alexander Eggermont4, Ken A. Olaussen1, Gilles Vassal7, Stefan Michiels 3, ✉ Fabrice Andre 1,4, Jean-Yves Scoazec5,6, Christophe Massard1,2, Jean-Charles Soria1,4, Benjamin Besse1,4 and Luc Friboulet 1 Unravelling the biological processes driving tumour resistance is necessary to support the development of innovative treatment strategies. We report the design and feasibility of the MATCH-R prospective trial led by Gustave Roussy with the primary objective of characterizing the molecular mechanisms of resistance to cancer treatments. The primary clinical endpoints consist of analyzing the type and frequency of molecular alterations in resistant tumours and compare these to samples prior to treatment. Patients experiencing disease progression after an initial partial response or stable disease for at least 24 weeks underwent a tumour biopsy guided by CT or ultrasound. Molecular profiling of tumours was performed using whole exome sequencing, RNA sequencing and panel sequencing. At data cut-off for feasibility analysis, out of 333 inclusions, tumour biopsies were obtained in 303 cases (91%). From these biopsies, 278 (83%) had sufficient quality for analysis by high-throughput next generation sequencing (NGS). All 278 samples underwent targeted NGS, 215 (70.9%) RNA sequencing and 222 (73.2%) whole 1234567890():,; exome sequencing.
    [Show full text]